Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Linagliptin/Metformin Extended Release Compared to the Free Combination of Empagliflozin, Linagliptin, and Metformin Extended Release Tablets Following Oral Administration in Healthy Male and Female Subjects (an Open-label, Randomised, Single-dose, Two-period, Two-sequence Crossover Study)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 03 Oct 2017
At a glance
- Drugs Empagliflozin/linagliptin/metformin (Primary) ; Empagliflozin; Linagliptin; Metformin
- Indications Diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 28 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 06 Sep 2017 Status changed from not yet recruiting to recruiting.
- 28 Aug 2017 New trial record